Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IV Non Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2011
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 14 May 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.